CCBIO Seminar – Shin Kaneko

Speaker: Shin Kaneko, Department of Cell Growth and Differentiation, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto City, Japan

Title: iPSC-based killer cell regeneration for cancer immunotherapy

Time: March 31, 2022 at 12.30

Place: Digital event in Zoom webinars. Use this audience link: https://uib.zoom.us/j/69581297802?pwd=REx6OEJMU3pKSGZyVjBvMG10RFR3QT09

Host: Jim Lorens

Abstract: For T cell immunotherapy, the important points for good clinical benefit is to keep antigen-specificity, younger memory function and a high quantity of T cells. Although CD19 CAR- T-cell immunotherapy has had tremendous success, some patients do not respond well because of insufficient quality and quantity of the patient’s T cell for CAR modification and CAR-T function in the body. iPS reprogramming technology can instill anti- cancer T cells a younger phenotype, clonality and quantity. Also, in cases using non-T cell derived non-antigen-specific iPS cells, antigen-specific receptor modification of the iPSC can give cancer-specificity to the differentiated T cells. To establish such a regenerative and rejuvenated T cell immunotherapy, we developed a system to efficiently produce T cells from iPS cells. In this presentation, we will introduce basic research and clinical development of iPSC-based immune cells modified by CAR.

References

1. Kawai Y, et al. Generation of highly proliferative, rejuvenated cytotoxic T cell clones through pluripotency reprograming for adoptive immunotherapy. Molecular Therapy 29(10):3027-3041.2021.    
2. Wang B, et al. Generation of hypoimmunogenic T cells from genetically engineered allogeneic human induced pluripotent stem cells. Nature Biomedical Engineering 2021(5):429-440.2021.    
3. Iriguchi S, Yasui Y, Kawai Y, et al. A clinically applicable and scalable method to regenerate T-cells from iPSCs for off-the-shelf T-cell immunotherapy. Nature Communications 2021(12) Article number: 430.2021.   
4. Ueda T, et al. Non-clinical efficacy, safety, and stable clinical cell processing of iPSC-derived anti-GPC3 CAR-expressing NK/ILC cells. Cancer Science 111(5):1478-1490.2020.
5. Xu H, Wang B, et al. Targeted Disruption of HLA Genes via CRISPR-Cas9 Generates iPSCs with Enhanced Immune Compatibility. Cell Stem Cell, 24(4):566-578.e7.
6. Minagawa A, et al. Enhancing T Cell Receptor Stability in Rejuvenated iPSC-Derived T Cells Improves Their Use in Cancer Immunotherapy. Cell Stem Cell. 23(6):850-858.e4.2018.    
7. Nishimura T, et al. Generation of rejuvenated antigen-specific T cells by reprogramming to pluripotency and redifferentiation. Cell Stem Cell. 12(1):114-26.2013

Bio: Professor Kaneko his MD and PhD degrees from the University of Tsukuba School of Medicine and completed residency in Internal Medicine at University of Tsukuba Hospital. After working as a Fellow of the Japan Society for the Promotion of Science in 2002 and a lecturer in the Department of Hematology, University of Tsukuba, he worked at the San Rafaele Institute in Italy from 2005 to 2008. After returning to Japan in 2008, he became an Assistant Professor at the Institute of Medical Sciences, University of Tokyo, an Associate Professor at the Center for iPS Cell Research and Application, Kyoto University in 2012, and a professor at the University of Tsukuba under the cross-appointment system with Kyoto University from 2020.

Professor Kaneko received the Japan Society for Hematology Young Investigator’s Award in 2002, the Japan Society for Gene Therapy Encouragement Award in 2010, and the Japan Society for Regenerative Medicine Innovation Award in 2012.
https://www.cira.kyoto-u.ac.jp/e/research/kaneko_summary.html

Zoom practicalities:

Note: Please change any username to your name when logging in, so that chair can address you by name if you have questions.

• Your sound and video will be turned off as default for security reasons, and only host can de-mute individual participants.
• We will open for questions after the lecture, where you can use the Raise hand function, or type your question in Chat. Host will then de-mute your sound and address you by your name (please log on with your name).
• If you think you might want to ask questions, please test your microphone beforehand. Make sure your microphone is turned on. (Or ask host to read out your typed question).
• We advise all to have a Zoom account on your device beforehand (free service), that will save you some minutes when logging on.

Those of us with University of Bergen (UiB) client machines, might already have Zoom. If not, see https://it.uib.no/Jeg_skal_bruke_Zoom_for_f%C3%B8rste_gang

For private machines (not UiB), see https://zoom.us/download#client_4meeting   Otherwise, clicking the logon link provided above will prompt the Zoom app to download, but it saves you time to have done this beforehand.